Hollow Brook Wealth Management LLC Has $4.34 Million Stock Position in Pfizer Inc. $PFE

Hollow Brook Wealth Management LLC increased its stake in shares of Pfizer Inc. (NYSE:PFE) by 24.3% during the 4th quarter, Holdings Channel reports. The institutional investor owned 174,152 shares of the biopharmaceutical company’s stock after buying an additional 34,001 shares during the period. Pfizer makes up 1.1% of Hollow Brook Wealth Management LLC’s holdings, making the stock its 25th biggest holding. Hollow Brook Wealth Management LLC’s holdings in Pfizer were worth $4,336,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the stock. Triad Wealth Partners LLC lifted its position in Pfizer by 1.9% during the 4th quarter. Triad Wealth Partners LLC now owns 20,466 shares of the biopharmaceutical company’s stock worth $510,000 after buying an additional 386 shares in the last quarter. ETF Store Inc. lifted its position in Pfizer by 3.8% during the 4th quarter. ETF Store Inc. now owns 10,913 shares of the biopharmaceutical company’s stock worth $272,000 after buying an additional 396 shares in the last quarter. Mattern Wealth Management LLC lifted its position in Pfizer by 4.6% during the 4th quarter. Mattern Wealth Management LLC now owns 9,161 shares of the biopharmaceutical company’s stock worth $228,000 after buying an additional 400 shares in the last quarter. Pines Wealth Management LLC lifted its position in Pfizer by 4.4% during the 4th quarter. Pines Wealth Management LLC now owns 9,430 shares of the biopharmaceutical company’s stock worth $235,000 after buying an additional 400 shares in the last quarter. Finally, Pathway Financial Advisers LLC raised its holdings in Pfizer by 0.9% during the 4th quarter. Pathway Financial Advisers LLC now owns 46,380 shares of the biopharmaceutical company’s stock worth $1,155,000 after purchasing an additional 403 shares during the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Price Performance

Pfizer stock opened at $26.01 on Tuesday. The firm has a market capitalization of $148.24 billion, a P/E ratio of 19.86 and a beta of 0.34. Pfizer Inc. has a 1 year low of $23.11 and a 1 year high of $28.75. The business has a 50-day moving average of $26.38 and a 200-day moving average of $26.33. The company has a current ratio of 1.25, a quick ratio of 0.94 and a debt-to-equity ratio of 0.67.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.72 by $0.03. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The business had revenue of $14.45 billion during the quarter, compared to analyst estimates of $13.84 billion. During the same period in the previous year, the firm earned $0.92 EPS. Pfizer’s quarterly revenue was up 5.4% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, equities analysts anticipate that Pfizer Inc. will post 2.99 EPS for the current year.

Pfizer Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, June 12th. Investors of record on Friday, May 8th were given a $0.43 dividend. The ex-dividend date was Friday, May 8th. This represents a $1.72 annualized dividend and a dividend yield of 6.6%. Pfizer’s payout ratio is currently 131.30%.

Key Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer’s obesity drug berobenatide posted encouraging Phase 2b results, with favorable tolerability and proof-of-concept data that could strengthen the company’s late-stage pipeline. Pfizer Obesity Pipeline Gains Traction As Berobenatide Data Support Valuation
• Positive Sentiment: Pfizer has been upgraded by RBC Capital, reinforcing optimism around the stock’s valuation and income appeal. Pfizer (PFE) Upgraded at RBC Capital. Here is Why
• Positive Sentiment: The CEO said Pfizer could eventually get back to high-single-digit growth, suggesting the business may be better positioned than some investors expect. Here’s When Pfizer’s CEO Says the Company Might Get Back to Generating High-Single-Digit Growth
• Neutral Sentiment: Multiple research and analyst roundups focused on Pfizer’s growth drivers, challenges, and recent stock performance, keeping the stock in the spotlight but without a major new catalyst. Top Research Reports for Pfizer & Newmont Corp.
• Neutral Sentiment: Pfizer was among the most searched stocks on Zacks, reflecting investor curiosity around what comes next for the name. Investors Heavily Search Pfizer Inc. (PFE): Here is What You Need to Know
• Neutral Sentiment: Coverage on Pfizer’s discounted valuation weighed the downside from fading COVID revenue and patent cliffs against upside from oncology, new products, and pipeline execution. Is Pfizer’s Discounted Valuation a Buying Opportunity or a Value Trap?

Analyst Upgrades and Downgrades

Several analysts have weighed in on PFE shares. Guggenheim boosted their price objective on Pfizer from $35.00 to $36.00 and gave the stock a “buy” rating in a report on Tuesday, March 24th. BMO Capital Markets reissued an “outperform” rating and set a $30.00 price objective on shares of Pfizer in a report on Monday, March 9th. CICC Research started coverage on Pfizer in a report on Thursday, April 16th. They set an “outperform” rating and a $33.00 price objective for the company. Zacks Research raised Pfizer from a “strong sell” rating to a “hold” rating in a report on Tuesday, February 24th. Finally, HSBC boosted their price objective on Pfizer from $29.00 to $32.00 and gave the stock a “buy” rating in a report on Tuesday, March 17th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, twelve have given a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, Pfizer presently has an average rating of “Hold” and a consensus target price of $28.82.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.